Cargando…
Therapeutic strategies to overcome ALK resistance in cancer /
"Therapeutic Strategies to Overcome ALK Resistance in Cancer, Volume 13, presents current strategies to improve and prolong clinical benefit in ALK driven cancers. Most patients with ALK-driven cancer are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops....
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
London, United Kingdom :
Academic Press, an imprint of Elsevier,
[2021]
|
| Colección: | Cancer sensitizing agents for chemotherapy ;
v. 13. |
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | SCIDIR_on1233309760 | ||
| 003 | OCoLC | ||
| 005 | 20231120010529.0 | ||
| 006 | m o d | ||
| 007 | cr ||||||||||| | ||
| 008 | 201116t20212021enkac ob 001 0 eng d | ||
| 040 | |a UKMGB |b eng |e rda |e pn |c UKMGB |d OCLCO |d UKAHL |d OPELS |d OCLCO |d OCLCF |d MMU |d OCLCO |d K6U |d OCLCQ |d CASUM |d OCLCO | ||
| 015 | |a GBC0I4637 |2 bnb | ||
| 016 | 7 | |a 020019926 |2 Uk | |
| 019 | |a 1235968798 | ||
| 020 | |a 9780128217795 |q electronic book ; |q epub | ||
| 020 | |a 0128217790 |q electronic book ; |q epub | ||
| 020 | |z 9780128217740 |q hardcover | ||
| 020 | |z 012821774X |q hardcover | ||
| 035 | |a (OCoLC)1233309760 |z (OCoLC)1235968798 | ||
| 050 | 4 | |a RC280.L8 | |
| 060 | 4 | |a WF 658 | |
| 082 | 0 | 4 | |a 616.9942406 |2 23 |
| 245 | 0 | 0 | |a Therapeutic strategies to overcome ALK resistance in cancer / |c edited by Luc Friboulet. |
| 264 | 1 | |a London, United Kingdom : |b Academic Press, an imprint of Elsevier, |c [2021] | |
| 264 | 4 | |c �2021 | |
| 300 | |a 1 online resource (xix, 195 pages) : |b illustrations (some color), portraits (some color). | ||
| 336 | |a text |2 rdacontent | ||
| 336 | |a still image |2 rdacontent | ||
| 337 | |a computer |2 rdamedia | ||
| 338 | |a online resource |2 rdacarrier | ||
| 490 | 1 | |a Cancer sensitizing agents for chemotherapy ; |v volume 13 | |
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | |a Structure and function of ALK -- ALK rearranged lung cancer: TKI treatment and outcome -- Systemic treatments other than TKI: reflections on chemotherapy, immunotherapy and antiangiogenic agents in ALK-driven NSCLC -- Management of ALK positive patients with tumors other than lung cancer (ALCL, neuroblastoma, inflammatory myofibroblastic tumor) -- Resistance mechanisms to ALK TKIs in lung cancer: from single to compound mutations, from tissue to liquid biopsy -- Resistance mechanisms to ALK TKI in tumors other than lung cancer -- Therapeutic strategies to overcome ALK resistance in lung cancer -- Novel therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALCL: use of ACD -- Drug combinations to enhance ALK TKI anti-tumor efficacy in neuroblastoma -- State of the art and future perspectives. | |
| 520 | |a "Therapeutic Strategies to Overcome ALK Resistance in Cancer, Volume 13, presents current strategies to improve and prolong clinical benefit in ALK driven cancers. Most patients with ALK-driven cancer are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops. This book discusses topics such as structure and function of ALK, ALK rearranged lung cancer, resistance mechanisms to ALK TKI tumors, and novel therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALCL. Additionally, it encompasses information on drug combinations to enhance ALK TKI anti-tumor efficacy in neuroblastoma and future perspectives in the field"--Publisher's description. | ||
| 588 | |a Description based on online resource; title from electronic title page (ProQuest Ebook Central, viewed on June 21, 2021). | ||
| 650 | 0 | |a Lungs |x Cancer |x Treatment. | |
| 650 | 1 | 2 | |a Anaplastic Lymphoma Kinase |x antagonists & inhibitors |0 (DNLM)D000077548Q000037 |
| 650 | 1 | 2 | |a Lung Neoplasms |x drug therapy |0 (DNLM)D008175Q000188 |
| 650 | 2 | 2 | |a Antineoplastic Agents |x pharmacology |0 (DNLM)D000970Q000494 |
| 650 | 2 | 2 | |a Protein Kinase Inhibitors |x therapeutic use |0 (DNLM)D047428Q000627 |
| 650 | 6 | |a Poumons |0 (CaQQLa)201-0029142 |x Cancer |0 (CaQQLa)201-0029142 |x Traitement. |0 (CaQQLa)201-0377521 | |
| 650 | 7 | |a Lungs |x Cancer |x Treatment |2 fast |0 (OCoLC)fst01003773 | |
| 655 | 4 | |a Internet Resources. | |
| 655 | 4 | |a Index not Present. | |
| 700 | 1 | |a Friboulet, Luc, |e editor. | |
| 776 | 0 | 8 | |i Print version : |t Therapeutic strategies to overcome ALK resistance in cancer. |d Amsterdam : Academic Press, 2021 |z 9780128217740 |w (OCoLC)1230544735 |
| 830 | 0 | |a Cancer sensitizing agents for chemotherapy ; |v v. 13. |x 2468-3183 | |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/science/book/9780128217740 |z Texto completo |